| Total | Women | Men |  | Dietary changes | Dietary supplements | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | % | n = 468 | % | n = 315 | % | n = 153 | p-value | % | n = 373 | p-value | % | n = 340 | p-value |
Sex | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.240* | Â | Â | 0.307* |
Women | 67.3 | 315 | Â | Â | Â | Â | Â | 80.1 | 246 | Â | 78.0 | 234 | Â |
Men | 32.7 | 153 | Â | Â | Â | Â | Â | 84.7 | 127 | Â | 73.6 | 106 | Â |
Age |  |  |  |  |  |  | < 0.001* |  |  | 0.675* |  |  | 0.035* |
19–50 years | 23.1 | 100 | 27.9 | 81 | 13.3 | 19 |  | 83.0 | 83 |  | 67.0 | 67 |  |
51–64 years | 41.3 | 179 | 43.4 | 126 | 37.1 | 53 |  | 79.3 | 142 |  | 80.4 | 144 |  |
65–82 years | 35.6 | 154 | 28.6 | 83 | 49.7 | 71 |  | 82.5 | 127 |  | 77.8 | 119 |  |
Mean age years (SD) | 59.18 (11.295) | 57.34 (11.277) | 62.92 (10.408) | < 0.001** | 58.98 (11.455) | 0.444** | 59.43 (11.420) | 0.889** | |||||
Education | Â | Â | Â | Â | Â | Â | 0.319* | Â | Â | 0.223* | Â | Â | 0.502* |
Primary school | 6.5 | 28 | 5.2 | 15 | 9.1 | 13 | Â | 71.4 | 20 | Â | 67.9 | 19 | Â |
Secondary school | 30.3 | 131 | 29.3 | 85 | 32.2 | 46 | Â | 85.5 | 112 | Â | 77.7 | 101 | Â |
College/ University < 4 years | 33.9 | 147 | 35.9 | 104 | 30.1 | 43 |  | 78.2 | 115 |  | 74.1 | 109 |  |
College/ University ≥ 4 years | 29.3 | 127 | 29.7 | 86 | 28.7 | 41 |  | 82.7 | 105 |  | 79.5 | 101 |  |
Household income | Â | Â | Â | Â | Â | Â | 0.477* | Â | Â | 0.937* | Â | Â | 0.482* |
Low (Less than EUR 40 000) | 10.4 | 45 | 10.3 | 30 | 10.5 | 15 | Â | 80.0 | 36 | Â | 75.6 | 34 | Â |
Middle (EUR 40 000 to 79 000) | 35.1 | 152 | 35.9 | 104 | 33.6 | 48 | Â | 80.3 | 122 | Â | 72.4 | 110 | Â |
High (EUR 80 000 or more) | 46.4 | 201 | 44.5 | 129 | 50.3 | 72 | Â | 82.6 | 166 | Â | 79.5 | 159 | Â |
No reply | 8.1 | 35 | 9.3 | 27 | 5.6 | 8 | Â | 80.0 | 28 | Â | 77.1 | 27 | Â |
Household1 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Live alone | 20.7 | 97 | 22.9 | 72 | 16.3 | 25 | 0.103* | 80.4 | 78 | 0.730* | 77.3 | 75 | 0.845* |
Live with a partner | 66.9 | 313 | 62.9 | 198 | 75.2 | 115 | 0.008* | 81.5 | 255 | 0.903* | 76.6 | 239 | 0.984* |
Live with own children | 18.2 | 85 | 21.3 | 67 | 11.8 | 18 | 0.012* | 78.8 | 37 | 0.461* | 68.2 | 58 | 0.043* |
Other | 1.5 | 7 | 1.6 | 5 | 1.3 | 2 | 1.000^ | 100 | 7 | 0.359^ | 71.4 | 5 | 0.668^ |
Place of residence (region) | Â | Â | Â | Â | Â | Â | 0.460* | Â | Â | 0.041^ | Â | Â | 0.384^ |
South-East | 51.7 | 242 | 53.3 | 168 | 48.4 | 74 | Â | 79.9 | 191 | Â | 73.7 | 171 | Â |
South | 4.3 | 20 | 4.1 | 13 | 4.6 | 7 | Â | 70.0 | 14 | Â | 80.0 | 16 | Â |
West | 24.8 | 116 | 22.5 | 71 | 29.4 | 45 | Â | 83.9 | 94 | Â | 77.1 | 84 | Â |
Central (Trøndelag) | 8.5 | 40 | 8.3 | 26 | 9.2 | 14 |  | 75.0 | 27 |  | 77.8 | 28 |  |
North | 10.7 | 50 | 11.7 | 34 | 8.5 | 13 | Â | 94.0 | 47 | Â | 87.2 | 41 | Â |
Cancer site1 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Breast | 39.1 | 183 | 57.8 | 182 | 0.7 | 1 | < 0.001* | 75.4 | 135 | 0.006* | 77.5 | 134 | 0.726* |
Gastro intestinal | 13.7 | 64 | 10.5 | 33 | 20.3 | 31 | 0.004* | 87.3 | 55 | 0.210* | 80.3 | 49 | 0.456* |
Male genitalia | 11.1 | 52 | - | - | 34.0 | 52 | - | 84.3 | 43 | 0.598* | 66.7 | 32 | 0.086* |
Female genitalia | 8.1 | 38 | 12.1 | 38 | - | - | - | 84.2 | 32 | 0.667* | 94.6 | 35 | 0.007* |
Lymphoma | 8.8 | 41 | 6.3 | 20 | 13.7 | 21 | 0.008* | 78.0 | 32 | 0.536* | 82.9 | 34 | 0314* |
Malignant melanoma | 4.7 | 22 | 4.4 | 14 | 5.2 | 8 | 0.707* | 90.9 | 20 | 0.249* | 59.1 | 13 | 0.047* |
Head and neck | 3.8 | 18 | 1.6 | 5 | 8.5 | 13 | < 0.001* | 83.3 | 15 | 0.848* | 82.4 | 14 | 0.773^ |
Lung | 3.2 | 15 | 2.5 | 8 | 4.6 | 7 | 0.268^ | 78.6 | 11 | 0.765* | 85.7 | 12 | 0.536^ |
Sarcoma | 3.0 | 14 | 3.8 | 12 | 1.3 | 2 | 0.160^ | 78.6 | 11 | 0.765* | 78.6 | 11 | 1.000^ |
Leukemia | 2.4 | 11 | 2.2 | 7 | 2.6 | 4 | 0.755^ | 90.9 | 10 | 0.421* | 72.7 | 8 | 0.724^ |
Bone marrow | 2.1 | 10 | 1.9 | 6 | 2.6 | 4 | 0.735^ | 100 | 10 | 0.129^ | 70.0 | 7 | 0.705^ |
Other cancer sites | 14.3 | 67 | 10.8 | 34 | 21.6 | 33 | 0.002* | 90.5 | 57 | 0.051* | 74.2 | 46 | 0.633* |
In active cancer treatment | Â | Â | Â | Â | Â | Â | 0.332* | Â | Â | 0.034* | Â | Â | 0.277* |
Yes | 33.8 | 158 | 35.2 | 111 | 30.7 | 47 | Â | 87.0 | 134 | Â | 79.6 | 121 | Â |
No | 66.2 | 310 | 64.8 | 204 | 69.3 | 106 | Â | 78.9 | 239 | Â | 75.0 | 129 | Â |
Late and long-term effects | Â | Â | Â | Â | Â | Â | Â 0.045* | Â | Â | Â 0.064* | Â | Â | Â 0.041* |
No | 11.5 | 50 | 8.9 | 26 | 16.8 | 24 | Â | 70.0 | 35 | Â | 64.0 | 32 | Â |
Yes, the following: | 82.9 | 360 | 84.9 | 247 | 79.0 | 113 | Â | 83.1 | 299 | Â | 78.6 | 282 | Â |
Fatigue | 54.9 | 257 | 58.4 | 184 | 47.7 | 73 | 0.029* | 84.0 | 216 | 0.129* | 80.5 | 207 | 0.021* |
Sleep disorder | 38.5 | 180 | 45.7 | 144 | 23.5 | 36 | < 0.001* | 85.6 | 154 | 0.080* | 82.2 | 148 | 0.020* |
Hot flushes | 36.3 | 170 | 46.0 | 145 | 16.3 | 25 | < 0.001* | 81.2 | 138 | 0.851* | 81.8 | 139 | 0.042* |
Nerve damage (polyneuropathy) | 35.3 | 165 | 42.2 | 133 | 20.9 | 32 | < 0.001* | 83.0 | 137 | 0.558* | 82.4 | 136 | 0.025* |
Pain | 34.0 | 159 | 40.0 | 126 | 21.6 | 33 | < 0.001* | 83.0 | 132 | 0.573* | 78.6 | 125 | 0.448* |
Decreased muscle strength and mobility | 33.8 | 158 | 39.4 | 124 | 22.2 | 34 | < 0.001* | 83.5 | 132 | 0.440* | 80.3 | 126 | 0.176* |
Cognitive challenges | 31.8 | 149 | 41.0 | 129 | 13.1 | 20 | < 0.001* | 84.6 | 126 | 0.258* | 83.2 | 124 | 0.019* |
Sexual problems | 29.3 | 137 | 26.7 | 84 | 34.6 | 53 | 0.075* | 83.9 | 115 | 0.402* | 78.8 | 108 | 0.453* |
Gained weight | 25.2 | 118 | 30.8 | 97 | 13.7 | 21 | < 0.001* | 86.4 | 102 | 0.116* | 83.9 | 88 | 0.028* |
Anxiety or depression | 20.5 | 96 | 22.5 | 71 | 16.3 | 25 | 0.119* | 91.7 | 88 | 0.004* | 86.5 | 83 | 0.010* |
Early menopause | 19.2 | 90 | 28.6 | 90 | - | - | - | 77.8 | 70 | 0.294* | 82.2 | 74 | 0.157* |